Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer
Tyrosine kinase inhibitors (TKI) play a pivotal role in the treatment of non-small-cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor (EGFR) and rearrangements in anaplastic lymphoma kinase (ALK). However, the influences of TKIs on the tumor immune microenvironment (TIM), es...
Main Authors: | Yisheng Fang, Yuanyuan Wang, Dongqiang Zeng, Shimeng Zhi, Tingting Shu, Na Huang, Siting Zheng, Jianhua Wu, Yantan Liu, Genjie Huang, Yichen Xue, Jianping Bin, Yulin Liao, Min Shi, Wangjun Liao |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2021.1951019 |
Similar Items
-
ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey
by: Gulden Diniz, et al.
Published: (2022-01-01) -
Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients
by: Liu J, et al.
Published: (2019-05-01) -
Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
by: Haoyue Hu, et al.
Published: (2023-08-01) -
Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports
by: Lionel Michaux, et al.
Published: (2023-06-01) -
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
by: Shoko Sonobe Shimamura, et al.
Published: (2022-03-01)